AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 228 filers reported holding AXSOME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,395,594 | +4.1% | 349,057 | +7.0% | 0.01% | 0.0% |
| Q2 2023 | $23,436,493 | +19.5% | 326,141 | +2.5% | 0.01% | +25.0% |
| Q1 2023 | $19,617,447 | -18.5% | 318,052 | +2.0% | 0.00% | -20.0% |
| Q4 2022 | $24,060,318 | +87.3% | 311,945 | +8.3% | 0.01% | +66.7% |
| Q3 2022 | $12,848,000 | +19.7% | 287,952 | +2.7% | 0.00% | +50.0% |
| Q2 2022 | $10,733,000 | -7.6% | 280,251 | -0.2% | 0.00% | 0.0% |
| Q1 2022 | $11,618,000 | +5.6% | 280,709 | -3.6% | 0.00% | 0.0% |
| Q4 2021 | $11,005,000 | +20.4% | 291,299 | +5.1% | 0.00% | 0.0% |
| Q3 2021 | $9,139,000 | -53.3% | 277,250 | -4.4% | 0.00% | -33.3% |
| Q2 2021 | $19,571,000 | +13.5% | 290,130 | -4.7% | 0.00% | 0.0% |
| Q1 2021 | $17,237,000 | -33.5% | 304,422 | -4.3% | 0.00% | -40.0% |
| Q4 2020 | $25,910,000 | +3.1% | 318,030 | -9.8% | 0.01% | -16.7% |
| Q3 2020 | $25,132,000 | -18.6% | 352,733 | -6.0% | 0.01% | -14.3% |
| Q2 2020 | $30,875,000 | +47.6% | 375,239 | +5.6% | 0.01% | +16.7% |
| Q1 2020 | $20,914,000 | -39.2% | 355,498 | +6.9% | 0.01% | -25.0% |
| Q4 2019 | $34,374,000 | +409.8% | 332,567 | -0.2% | 0.01% | +300.0% |
| Q3 2019 | $6,743,000 | +190.0% | 333,147 | +269.1% | 0.00% | +100.0% |
| Q2 2019 | $2,325,000 | +362.2% | 90,263 | +155.3% | 0.00% | – |
| Q1 2019 | $503,000 | +484.9% | 35,358 | +15.9% | 0.00% | – |
| Q4 2018 | $86,000 | -18.1% | 30,515 | 0.0% | 0.00% | – |
| Q3 2018 | $105,000 | +8.2% | 30,515 | 0.0% | 0.00% | – |
| Q2 2018 | $97,000 | +29.3% | 30,515 | 0.0% | 0.00% | – |
| Q1 2018 | $75,000 | -60.5% | 30,515 | -10.2% | 0.00% | – |
| Q4 2017 | $190,000 | -2.1% | 33,992 | -2.8% | 0.00% | – |
| Q3 2017 | $194,000 | +1.0% | 34,966 | 0.0% | 0.00% | – |
| Q2 2017 | $192,000 | -56.1% | 34,966 | -68.8% | 0.00% | – |
| Q1 2017 | $437,000 | -38.5% | 112,199 | +6.6% | 0.00% | – |
| Q4 2016 | $711,000 | -14.0% | 105,233 | +0.3% | 0.00% | – |
| Q3 2016 | $827,000 | +404.3% | 104,957 | +383.9% | 0.00% | – |
| Q2 2016 | $164,000 | – | 21,692 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |